ProQR Therapeutics NV Company Profile (NASDAQ:PRQR)

About ProQR Therapeutics NV

ProQR Therapeutics NV logoProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber's congenital amaurosis (LCA). It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010 and QR-110. It is focusing on developing QRX- 911, QRX- 021, QRX- 313, QRX- 704, QRX- 812, QRX- 411, QRX- 504, QRX- 604 and QRX- 203. QR-010 is an RNA-based oligonucleotide. QR-110, is an oligonucleotide.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PRQR
  • CUSIP:
Key Metrics:
  • Previous Close: $5.81
  • 50 Day Moving Average: $5.01
  • 200 Day Moving Average: $4.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.86
  • P/E Growth: 0.00
  • Market Cap: $135.64M
  • Outstanding Shares: 23,346,000
  • Beta: 1
Additional Links:
Companies Related to ProQR Therapeutics NV:

Analyst Ratings

Consensus Ratings for ProQR Therapeutics NV (NASDAQ:PRQR) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $19.50 (235.63% upside)

Analysts' Ratings History for ProQR Therapeutics NV (NASDAQ:PRQR)
Show:
DateFirmActionRatingPrice TargetDetails
8/18/2016Leerink SwannReiterated RatingBuyView Rating Details
6/20/2016Chardan CapitalInitiated CoverageNeutral$4.50View Rating Details
3/15/2016JMP SecuritiesLower Price TargetMarket Outperform$24.00 -> $14.00View Rating Details
1/6/2016HC WainwrightReiterated RatingBuy$40.00View Rating Details
10/15/2014Deutsche Bank AGInitiated CoverageBuy$32.00View Rating Details
10/13/2014Jefferies GroupInitiated CoverageOutperform$24.00View Rating Details
(Data available from 8/24/2014 forward)

Earnings

Earnings History for ProQR Therapeutics NV (NASDAQ:PRQR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/21/2016        
8/17/2016Q2($0.48)($0.48)ViewN/AView Earnings Details
5/18/2016Q1($0.41)($0.50)ViewN/AView Earnings Details
2/17/2016Q4($0.35)($0.29)ViewN/AView Earnings Details
11/23/2015Q3($0.36)($0.29)ViewN/AView Earnings Details
8/19/2015($0.32)($0.41)ViewN/AView Earnings Details
5/21/2015($0.29)$0.01ViewN/AView Earnings Details
2/26/2015($0.27)($0.30)ViewN/AView Earnings Details
11/24/2014($1.00)($0.53)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ProQR Therapeutics NV (NASDAQ:PRQR)
Current Year EPS Consensus Estimate: $-1.80 EPS
Next Year EPS Consensus Estimate: $-2.03 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.63)($0.63)($0.63)
Q4 20161($0.75)($0.75)($0.75)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ProQR Therapeutics NV (NASDAQ:PRQR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ProQR Therapeutics NV (NASDAQ:PRQR)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for ProQR Therapeutics NV (NASDAQ:PRQR)
DateHeadline
publicnow.com logoProQR Announces Results for the Second Quarter of 2016 (NASDAQ:PRQR)
www.publicnow.com - August 17 at 9:56 AM
finance.yahoo.com logoProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis (NASDAQ:PRQR)
finance.yahoo.com - July 19 at 7:00 AM
publicnow.com logoProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC (NASDAQ:PRQR)
www.publicnow.com - June 21 at 9:19 AM
finance.yahoo.com logoCoverage initiated on ProQR Therapeutics by Chardan Capital Markets (NASDAQ:PRQR)
finance.yahoo.com - June 20 at 5:50 AM
capitalcube.com logoProQR Therapeutics NV :PRQR-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 (NASDAQ:PRQR)
www.capitalcube.com - June 8 at 6:03 PM
publicnow.com logoProQR Announces Presentations at the European CF Conference and the JMP Life Science Conference (NASDAQ:PRQR)
www.publicnow.com - June 1 at 7:23 AM
publicnow.com logoProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation (NASDAQ:PRQR)
www.publicnow.com - June 1 at 7:23 AM
finance.yahoo.com logo7:04 am ProQR Therapeutics confirms that its investigational drug QR-110 has received orphan drug designation from both the FDA and the EMA for the treatment of Leber's congenital amaurosis Type 10 (NASDAQ:PRQR)
finance.yahoo.com - June 1 at 7:04 AM
publicnow.com logoProQR Announces Results for the First Quarter of 2016 (NASDAQ:PRQR)
www.publicnow.com - May 18 at 7:42 AM
sg.finance.yahoo.com logoProQR reports 1Q loss (NASDAQ:PRQR)
sg.finance.yahoo.com - May 18 at 7:23 AM
sg.finance.yahoo.com logoProQR reports 4Q loss (NASDAQ:PRQR)
sg.finance.yahoo.com - February 17 at 7:19 AM
finance.yahoo.com logoProQR to Present at the Leerink Partners Global Healthcare Conference (NASDAQ:PRQR)
finance.yahoo.com - February 3 at 7:00 AM
finance.yahoo.com logoWhy ProQR Therapeutics (PRQR) Stock Might be a Great Pick (NASDAQ:PRQR)
finance.yahoo.com - December 22 at 8:33 AM
insidermonkey.com logoHedge Funds Aren’t Crazy About ProQR Therapeutics NV (PRQR) Anymore (NASDAQ:PRQR)
www.insidermonkey.com - December 14 at 9:24 PM
finance.yahoo.com logoProQR Therapeutics (PRQR) Rises: Stock Up 6.1% in Session (NASDAQ:PRQR)
finance.yahoo.com - December 9 at 8:45 AM
finance.yahoo.com logoPROQR THERAPEUTICS N.V. Financials (NASDAQ:PRQR)
finance.yahoo.com - December 8 at 1:09 PM
finance.yahoo.com logoProQR Announces R&D Day and Provides Update on Innovation Portfolio (NASDAQ:PRQR)
finance.yahoo.com - November 30 at 7:00 AM
finance.yahoo.com logoProQR Therapeutics (PRQR) Falls: Stock Goes Down 24.8% (NASDAQ:PRQR)
finance.yahoo.com - November 24 at 8:50 AM
noodls.com logoProQR Announces Results for the Third Quarter of 2015 and Provides Update on Clinical Trials (NASDAQ:PRQR)
www.noodls.com - November 23 at 7:02 AM
sg.finance.yahoo.com logoProQR reports 3Q loss (NASDAQ:PRQR)
sg.finance.yahoo.com - November 23 at 6:39 AM
noodls.com logoProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-010 for Cystic Fibrosis at Two Upcoming Scientific Conferences (NASDAQ:PRQR)
www.noodls.com - October 1 at 7:18 AM
noodls.com logoProQR Announces a Proof-of-Concept Nasal Potential Difference Study of QR-010 is Open for Enrollment (NASDAQ:PRQR)
www.noodls.com - September 14 at 7:15 AM
noodls.com logoProQR Announces Results for the Second Quarter of 2015 (NASDAQ:PRQR)
www.noodls.com - August 19 at 8:38 AM
sg.finance.yahoo.com logoProQR reports 2Q loss (NASDAQ:PRQR)
sg.finance.yahoo.com - August 19 at 8:15 AM

Social

ProQR Therapeutics NV (NASDAQ:PRQR) Chart for Wednesday, August, 24, 2016


Last Updated on 8/24/2016 by MarketBeat.com Staff